Phobic Disorders

• 

  Subject Areas on Research

  • A 2-year follow-up of social phobia. Status after a brief medication trial. 
  • A cognitive model of anxiety formation and anxiety resolution. 
  • A contextual approach to experiential avoidance and social anxiety: evidence from an experimental interaction and daily interactions of people with social anxiety disorder. 
  • A model of the development and maintenance of generalized social phobia. 
  • A repeat proton magnetic resonance spectroscopy study in social phobia. 
  • An examination of the relationship between behavioral approach system (BAS) sensitivity and social interaction anxiety. 
  • Analysis of shortened versions of the tampa scale for kinesiophobia and pain catastrophizing scale for patients after anterior cruciate ligament reconstruction. 
  • Anxiety Disorders in Caucasian and African American Children: A Comparison of Clinical Characteristics, Treatment Process Variables, and Treatment Outcomes. 
  • Anxiety in middle adulthood: effects of age and time on the 14-year course of panic disorder, social phobia and generalized anxiety disorder. 
  • Association between amygdala reactivity and a dopamine transporter gene polymorphism. 
  • Attention bias toward threat in pediatric anxiety disorders. 
  • Belief in life after death and mental health: findings from a national survey. 
  • Benefits of child-focused anxiety treatments for parents and family functioning. 
  • Biological characterization of social phobia. 
  • Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial. 
  • Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. 
  • Child/Adolescent anxiety multimodal study: evaluating safety. 
  • Clinical characteristics of anxiety disordered youth. 
  • Comparison of lifetime psychiatric diagnoses in Premenstrual Syndrome Clinic and community samples. 
  • Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. 
  • Defining an appropriate management strategy for social anxiety disorder. 
  • Demographics, treatment seeking, and diagnoses of anxiety support group participants. 
  • Developing a framework to describe stigma related to cervical cancer and HPV in western Kenya. 
  • Diagnostic specificity and nonspecificity in the dimensions of preschool psychopathology. 
  • Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. 
  • Discontinuation of clonazepam in the treatment of social phobia. 
  • Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression? 
  • Easing the burden of social anxiety disorder. 
  • Efficacy of olanzapine in social anxiety disorder: a pilot study. 
  • Efficient Screening for Fear of Movement in Outpatient Settings: Short Form and Computer Adaptive Tests for Fear Avoidance and Negative Pain Coping. 
  • Emotional processing and fear measurement synchrony as indicators of treatment outcome in fear of flying. 
  • Escitalopram in specific phobia: results of a placebo-controlled pilot trial. 
  • Fear is associated with attrition of first-time whole blood donors: A longitudinal examination of donor confidence and attitude as potential mediators. 
  • Fear of movement (kinesiophobia), pain, and psychopathology in patients with sickle cell disease. 
  • Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. 
  • Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. 
  • Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. 
  • Generalized social anxiety disorder and avoidant personality disorder: structural analysis and treatment outcome. 
  • Graded exposure therapy for addressing claustrophobic reactions to continuous positive airway pressure: a case series report. 
  • How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. 
  • Hyperhidrosis in social anxiety disorder. 
  • Impact of generalized social anxiety disorder in managed care. 
  • Indicators of pretreatment suicidal ideation in adults with major depressive disorder. 
  • International advances in the treatment of social phobia. 
  • Juvenile mental health histories of adults with anxiety disorders. 
  • Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. 
  • Levels of urinary free cortisol in social phobia. 
  • Levetiracetam in social phobia: a placebo controlled pilot study. 
  • Links between growth hormone deficiency, adaptation and social phobia. 
  • Long-term treatment of social phobia with clonazepam. 
  • Magnetic resonance imaging in social phobia. 
  • Magnetic resonance spectroscopy in social phobia: preliminary findings. 
  • Mediators of change in the Child/Adolescent Anxiety Multimodal Treatment Study. 
  • Meeting of minds in psychiatry and homeopathy: an example in social phobia. 
  • Mini-SPIN: A brief screening assessment for generalized social anxiety disorder. 
  • Moclobemide in social phobia: a controlled dose-response trial. 
  • Morbid obesity is associated with fear of movement and lower quality of life in patients with knee pain-related diagnoses. 
  • Multidimensional effects of sertraline in social anxiety disorder. 
  • Neurologic and neuroscience education: Mitigating neurophobia to mentor health care providers. 
  • PDI-4A: an augmented provisional screening instrument assessing 5 additional common anxiety-related diagnoses in adult primary care patients. 
  • Panic disorder and social phobia: current treatments and new strategies. 
  • Parental anxiety as a predictor of medication and CBT response for anxious youth. 
  • Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. 
  • Perceived stress in anxiety disorders and the general population: a study of the Sheehan stress vulnerability scale. 
  • Pharmacotherapy of social anxiety disorder. 
  • Pharmacotherapy of social anxiety disorder: what does the evidence tell us? 
  • Pharmacotherapy of social phobia. 
  • Phobia: prevalence and risk factors. 
  • Phobic anxiety and increased risk of mortality in coronary heart disease. 
  • Phobic anxiety, depression, and risk of ventricular arrhythmias in patients with coronary heart disease. 
  • Preschool anxiety disorders in pediatric primary care: prevalence and comorbidity. 
  • Prevalence of anxiety disorders in men and women with established coronary heart disease. 
  • Psychiatric disorders in adult children of alcoholics: data from the Epidemiologic Catchment Area project. 
  • Psychological predictors of recovery from low back pain: a prospective study. 
  • Psychometric properties of the Fear-Avoidance Beliefs Questionnaire and Tampa Scale of Kinesiophobia in patients with shoulder pain. 
  • Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale. 
  • Reading problems, psychiatric disorders, and functional impairment from mid- to late adolescence. 
  • Resolution of fear of flying with fluoxetine treatment. 
  • Secondary agoraphobia: two case reports. 
  • Self-discrepancies in clinical depression and social phobia: cognitive structures that underlie emotional disorders? 
  • Sensitivity to punishment and low maternal care account for the link between bulimic and social anxiety symptomology. 
  • Short stature, growth hormone deficiency, and social anxiety. 
  • Social and personal resources and the prevalence of phobic disorder in a community population. 
  • Social anxiety disorder in children and adolescents: epidemiology, diagnosis, and treatment. 
  • Social anxiety disorder in review: two decades of progress. 
  • Social phobia and separation anxiety symptoms in community and clinical samples of children and adolescents. 
  • Social phobia: biological aspects and pharmacotherapy. 
  • Social phobia: issues in assessment and management. 
  • Social phobia: outlook for the '90s. 
  • Study refusal and exclusion from a randomized treatment study of generalized social phobia. 
  • Symptomatic and functional assessment of social anxiety disorder in adults. 
  • The Brief Social Phobia Scale. 
  • The Brief Social Phobia Scale: a psychometric evaluation. 
  • The boundary of social phobia. Exploring the threshold. 
  • The effects of childhood parental death and divorce on six-month history of anxiety disorders. 
  • The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. 
  • The neurobiology of social phobia. 
  • The relationship between panic disorder and agoraphobia: an epidemiologic perspective. 
  • The role of nuclear magnetic resonance imaging in psychiatric research. 
  • The therapeutic relationship in cognitive-behavioral therapy and pharmacotherapy for anxious youth. 
  • The use of ambulatory services by persons with and without phobia. 
  • Treatment of social phobia with benzodiazepines. 
  • Treatment of social phobia with clonazepam and placebo. 
  • Treatment of social phobia with gabapentin: a placebo-controlled study. 
  • Use of an automated bolus calculator reduces fear of hypoglycemia and improves confidence in dosage accuracy in patients with type 1 diabetes mellitus treated with multiple daily insulin injections. 
  • Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder. 
  • Use of in vivo desensitization to treat a patient's claustrophobic response to nasal CPAP. 
  • Variation of human amygdala response during threatening stimuli as a function of 5'HTTLPR genotype and personality style. 
  • What do childhood anxiety disorders predict? 
• 

  Keywords of People

  • Charles, Hal Cecil, Adjunct Associate Professor in the Department of Radiology, Radiology
  • Kimbrel, Nathan Andrew, Associate Professor in Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology